FATE THERAPEUTICS INC (FATE) Fundamental Analysis & Valuation

NASDAQ:FATE • US31189P1021

Current stock price

1.1 USD
+0.02 (+1.85%)
At close:
1.13 USD
+0.03 (+2.73%)
After Hours:

This FATE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. FATE Profitability Analysis

1.1 Basic Checks

  • FATE had negative earnings in the past year.
  • In the past year FATE has reported a negative cash flow from operations.
  • In the past 5 years FATE always reported negative net income.
  • In the past 5 years FATE always reported negative operating cash flow.
FATE Yearly Net Income VS EBIT VS OCF VS FCFFATE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -42.74%, FATE perfoms like the industry average, outperforming 55.71% of the companies in the same industry.
  • With a Return On Equity value of -65.79%, FATE perfoms like the industry average, outperforming 56.09% of the companies in the same industry.
Industry RankSector Rank
ROA -42.74%
ROE -65.79%
ROIC N/A
ROA(3y)-38.93%
ROA(5y)-35.95%
ROE(3y)-55.97%
ROE(5y)-51.48%
ROIC(3y)N/A
ROIC(5y)N/A
FATE Yearly ROA, ROE, ROICFATE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FATE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FATE Yearly Profit, Operating, Gross MarginsFATE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. FATE Health Analysis

2.1 Basic Checks

  • FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, FATE has more shares outstanding
  • The number of shares outstanding for FATE has been increased compared to 5 years ago.
  • FATE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FATE Yearly Shares OutstandingFATE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
FATE Yearly Total Debt VS Total AssetsFATE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -6.92, we must say that FATE is in the distress zone and has some risk of bankruptcy.
  • FATE has a worse Altman-Z score (-6.92) than 66.92% of its industry peers.
  • There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.92
ROIC/WACCN/A
WACC8.89%
FATE Yearly LT Debt VS Equity VS FCFFATE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 5.79 indicates that FATE has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 5.79, FATE is doing good in the industry, outperforming 61.12% of the companies in the same industry.
  • FATE has a Quick Ratio of 5.79. This indicates that FATE is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 5.79, FATE is doing good in the industry, outperforming 62.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.79
Quick Ratio 5.79
FATE Yearly Current Assets VS Current LiabilitesFATE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. FATE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.88% over the past year.
  • Looking at the last year, FATE shows a very negative growth in Revenue. The Revenue has decreased by -51.24% in the last year.
  • The Revenue for FATE have been decreasing by -26.71% on average. This is quite bad
EPS 1Y (TTM)29.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.64%
Revenue 1Y (TTM)-51.24%
Revenue growth 3Y-58.98%
Revenue growth 5Y-26.71%
Sales Q2Q%-26.4%

3.2 Future

  • Based on estimates for the next years, FATE will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.43% on average per year.
  • Based on estimates for the next years, FATE will show a very strong growth in Revenue. The Revenue will grow by 93.77% on average per year.
EPS Next Y2.19%
EPS Next 2Y1.83%
EPS Next 3Y-3.57%
EPS Next 5Y8.43%
Revenue Next Year-21.85%
Revenue Next 2Y-11.13%
Revenue Next 3Y7.06%
Revenue Next 5Y93.77%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FATE Yearly Revenue VS EstimatesFATE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
FATE Yearly EPS VS EstimatesFATE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. FATE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FATE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FATE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FATE Price Earnings VS Forward Price EarningsFATE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FATE Per share dataFATE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • FATE's earnings are expected to decrease with -3.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.83%
EPS Next 3Y-3.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FATE Dividend Analysis

5.1 Amount

  • FATE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FATE Fundamentals: All Metrics, Ratios and Statistics

FATE THERAPEUTICS INC

NASDAQ:FATE (3/20/2026, 7:29:42 PM)

After market: 1.13 +0.03 (+2.73%)

1.1

+0.02 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners78.4%
Inst Owner Change0.12%
Ins Owners1.42%
Ins Owner Change4.34%
Market Cap127.89M
Revenue(TTM)6.65M
Net Income(TTM)-136.31M
Analysts77.78
Price Target5.04 (358.18%)
Short Float %8.38%
Short Ratio5.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.46%
Min EPS beat(2)1.85%
Max EPS beat(2)9.06%
EPS beat(4)4
Avg EPS beat(4)11.49%
Min EPS beat(4)1.85%
Max EPS beat(4)18.09%
EPS beat(8)8
Avg EPS beat(8)11.64%
EPS beat(12)12
Avg EPS beat(12)17.48%
EPS beat(16)16
Avg EPS beat(16)16.78%
Revenue beat(2)2
Avg Revenue beat(2)6.52%
Min Revenue beat(2)1.86%
Max Revenue beat(2)11.18%
Revenue beat(4)4
Avg Revenue beat(4)34.46%
Min Revenue beat(4)1.86%
Max Revenue beat(4)84.97%
Revenue beat(8)8
Avg Revenue beat(8)91.82%
Revenue beat(12)11
Avg Revenue beat(12)69.18%
Revenue beat(16)14
Avg Revenue beat(16)69.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.96%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)3.92%
EPS NY rev (3m)3.92%
Revenue NQ rev (1m)29.19%
Revenue NQ rev (3m)29.19%
Revenue NY rev (1m)6.74%
Revenue NY rev (3m)6.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.24
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0.06
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.74%
ROE -65.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.93%
ROA(5y)-35.95%
ROE(3y)-55.97%
ROE(5y)-51.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.14%
Cap/Sales 89.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.79
Quick Ratio 5.79
Altman-Z -6.92
F-Score2
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)27.88%
Cap/Depr(5y)241.76%
Cap/Sales(3y)34.87%
Cap/Sales(5y)46.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.64%
EPS Next Y2.19%
EPS Next 2Y1.83%
EPS Next 3Y-3.57%
EPS Next 5Y8.43%
Revenue 1Y (TTM)-51.24%
Revenue growth 3Y-58.98%
Revenue growth 5Y-26.71%
Sales Q2Q%-26.4%
Revenue Next Year-21.85%
Revenue Next 2Y-11.13%
Revenue Next 3Y7.06%
Revenue Next 5Y93.77%
EBIT growth 1Y24.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.66%
OCF growth 3YN/A
OCF growth 5YN/A

FATE THERAPEUTICS INC / FATE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for FATE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to FATE.


Can you provide the valuation status for FATE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FATE THERAPEUTICS INC (FATE). This can be considered as Overvalued.


What is the profitability of FATE stock?

FATE THERAPEUTICS INC (FATE) has a profitability rating of 1 / 10.